GlassScriptPhysician profile
Samuel Jay Peretsman
NPI 1912946336
$9,600.60
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,511 · 2020: $2,818 · 2021: $1,495 · 2022: $2,164 · 2023: $372 · 2024: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,788.00 | 2020 | |
| Boston Scientific Corporation | $1,286.61 | 2019-2022 | |
| Astellas Pharma US INC | $1,176.85 | 2019-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $471.46 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $413.70 | 2019-2022 | |
| Janssen Biotech, INC. | $352.44 | 2019-2022 | |
| Antares Pharma, INC. | $346.64 | 2019-2022 | |
| Angiodynamics, INC. | $342.62 | 2019-2022 | |
| Coloplast Corp | $274.27 | 2019-2024 | Speedicath |
| Blue Earth Diagnostics | $256.88 | 2019-2022 | |
| Urogen Pharma, INC. | $246.87 | 2020-2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $241.11 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $225.97 | 2019-2021 | |
| Agiliti Surgical, INC. | $221.89 | 2023-2024 | Cryocare Cs, Sonablate, Sonablate Hifu |
| Urovant Sciences INC | $194.37 | 2021-2022 |
Show all 43 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Peretsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.